QI
TEVA icon

Qtron Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Qtron Investments’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,423
Closed -$392K – 477
2023
Q3 		$392K Buy
+38,423
New +$358K 0.07% 331
2023
Q2 		– Sell
-13,759
Closed -$122K – 438
2023
Q1 		$122K Buy
+13,759
New +$136K 0.03% 401
2021
Q3 		– Sell
-32,105
Closed -$318K – 381
2021
Q2 		$318K Hold
32,105
– – 0.08% 271
2021
Q1 		$370K Hold
32,105
– – 0.1% 238
2020
Q4 		$310K Buy
+32,105
New +$308K 0.08% 270

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Qtron Investments's TEVA Position: Q4 2023 in Review

Qtron Investments sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 38,423 shares — an estimated $392K sold.

Qtron Investments first reported a position in TEVA in Q4 2020 and held it in 5 quarters. The position peaked at $392K in Q3 2023. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Qtron Investments reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Qtron Investments sold 38,423 Teva Pharmaceuticals shares in Q4 2023, an estimated $392K.
  • Qtron Investments first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Qtron Investments's Teva Pharmaceuticals position peaked at $392K in Q3 2023.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Qtron Investments's 13F filing for Q4 2023, filed 12 Feb 2024.